PATHOGENESIS, DIAGNOSIS, AND TREATMENT OF SYSTEMIC SCLEROSIS – AN INTEGRATIVE REVIEW OF THE CURRENT APPROACHES
Authors:
- Olaf KrawczykOKOlaf Krawczyk
- Wojciech KopycińskiWKWojciech Kopyciński
- Norbert KrawczykNKNorbert Krawczyk
- Piotr WilczkowskiPWPiotr Wilczkowski
- Natalia KrzysztofekNKNatalia Krzysztofek
- Monika KamelaMKMonika Kamela
- Katarzyna BoszczykKBKatarzyna Boszczyk
- Małgorzata GrzybowskaMGMałgorzata Grzybowska
- Adrianna BaranABAdrianna Baran
- Aleksandra PalkaAPAleksandra Palka
Open Access
- 2 July 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Abstract
Systemic sclerosis is a rare autoimmune connective tissue disorder marked by immunological dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs, resulting in considerable morbidity and mortality. The disease results from a complex interaction between genetic susceptibility, epigenetic modifications, environmental triggers, endothelial dysfunction, and aberrant immune responses. These mechanisms promote persistent inflammation, stimulation of fibroblasts and abundant extracellular matrix deposition, eventually causing irreversible tissue fibrosis and organ dysfunction. The diagnosis is based on clinical manifestations, supported by specific antibodies detection, capillaroscopy, and appropriate functional and imaging tests. To facilitate diagnosis, the American College of Rheumatology/European League Against Rheumatism issued guidelines in 2013, enabling earlier diagnosis and more accurate prognostic assessment. Although no curative therapy is currently available, treatment has advanced considerably and focuses on suppressing disease activity, slowing fibrosis, and preventing organ complications. Current therapeutic strategies include immunosuppressive agents, biologic therapies, antifibrotic drugs, and targeted vasodilator treatments tailored to individual organ involvement. Emerging approaches, such as JAK-STAT pathway inhibitors, CAR-T cell therapy, and stem cell transplantation, may further improve long-term outcomes in selected patients. Despite substantial progress in understanding disease mechanisms and expanding therapeutic options, systemic sclerosis remains a clinically heterogeneous disorder requiring early diagnosis, multidisciplinary management, and individualized treatment to optimize survival and quality of life.Keywords
This publication has 80 references indexed in Scilit:
- A Practical Approach to the Management of Digital Ulcers in Patients With Systemic SclerosisJAMA Dermatology, 2021
- Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo‐Controlled TrialsArthritis Care & Research, 2017
- Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic SclerosisJAMA, 2014
- Review: Evidence That Systemic Sclerosis Is a Vascular DiseaseArthritis & Rheumatism, 2013
- Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodiesArthritis & Rheumatism, 2010
- BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4Arthritis & Rheumatism, 2009
- Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty‐year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosisArthritis & Rheumatism, 2008
- Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblastsArthritis & Rheumatism, 2006
- Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonistArthritis & Rheumatism, 2004
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001